US FDA approves Replimune's skin cancer drug after prior rejections - Reuters
US FDA approves Replimune's skin cancer drug after prior rejections Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQSzRDTVZPLXhNYTNDWDYyVXZTemQwOXJNQVlVblBvZHVpbUxPX0dQQzVRVTJIT2h5ZmFjVGlOZjNScjRPT1FveDliRmtNdEh5WEtNWUF4Sk5xVi1qdV9aQ3A3eEZvWHNGUDFCWGNhT0ZEb2gwdWw1amRPWkJ2d1M4em1VVVZCdUM3YW9JLXhMamVWOUFseVZnNTd3OWFwaFdWdy1VNVlITVVqUWR6dFYzZ0xFRzlGZw?oc=5" target="_blank">US FDA approves Replimune's skin cancer drug after prior rejections</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
US FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie's drug for Parkinson's disease reuters.com
September 25, 2026 at 10:57 PMAstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination - Reuters
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination Reuters
October 2, 2026 at 06:58 AMMerck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
September 28, 2026 at 04:14 PMAbbVie joins US government pilot to test drug discount rebates - Reuters
AbbVie joins US government pilot to test drug discount rebates Reuters
October 2, 2026 at 08:53 PMExperimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters
Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
September 30, 2026 at 05:34 PMFDA seeks scientists and consumer representatives for advisory panels - reuters.com
FDA seeks scientists and consumer representatives for advisory panels reuters.com
September 30, 2026 at 08:30 PM